Education
About Us
Working with TipRanks
Follow Us
Joint Corp (JYNT)
NASDAQ:JYNT
JYNT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.04 - $13.47
Previous CloseN/A
Volume11.07K
Average Volume (3M)96.27K
Market Cap
$123.67M
Enterprise Value$148.92M
Total Cash (Recent Filing)$29.81M
Total Debt (Recent Filing)$2.17M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Nov 06, 2025Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding15,343,377
10 Day Avg. Volume118,997
30 Day Avg. Volume96,267
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)8.85
Price to Sales (P/S)3.06
P/FCF Ratio19.27
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue2.79
Enterprise Value/Gross Profit3.61
Enterprise Value/Ebitda88.71
Forecast
1Y Price Target
$14.00Price Target Upside73.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Cash Flow And Financial HealthJYNT had $29.8M in unrestricted cash and no debt, and is expected to generate positive cash flows from continuing operations.
Digital StrategyThe Joint is advancing its digital strategy, with increased online scheduling capabilities and the launch of its first mobile app expected, which could improve the patient experience and drive repeat visits.
Strategic InitiativesThe recent deal to refranchise 31 clinics and reacquire regional developer territory rights for the Northwest region for $8.3M is viewed as a positive step toward operational efficiency and strategic clarity.
Bears Say
Execution RisksExecution risks remain, as the company has yet to finalize the sale of a significant number of corporate-owned clinics.
Operational UncertaintyThe potential sale, relocation, or closure of company-owned clinics creates uncertainty.
Revenue Growth And Sales OutlookJYNT's reduced sales outlook and weakening revenue growth reflect mounting headwinds in patient acquisition and a deliberate slowdown in clinic expansion.
Joint News
JYNT FAQ
What was Joint Corp’s price range in the past 12 months?
Joint Corp lowest stock price was $8.04 and its highest was $13.47 in the past 12 months.
What is Joint Corp’s market cap?
Joint Corp’s market cap is $123.67M.
When is Joint Corp’s upcoming earnings report date?
Joint Corp’s upcoming earnings report date is Nov 06, 2025 which is in 23 days.
How were Joint Corp’s earnings last quarter?
Joint Corp released its earnings results on Aug 07, 2025. The company reported -$0.053 earnings per share for the quarter, missing the consensus estimate of -$0.043 by -$0.01.
Is Joint Corp overvalued?
According to Wall Street analysts Joint Corp’s price is currently Undervalued.
Does Joint Corp pay dividends?
Joint Corp does not currently pay dividends.
What is Joint Corp’s EPS estimate?
Joint Corp’s EPS estimate is 0.
How many shares outstanding does Joint Corp have?
Joint Corp has 15,343,377 shares outstanding.
What happened to Joint Corp’s price movement after its last earnings report?
Joint Corp reported an EPS of -$0.053 in its last earnings report, missing expectations of -$0.043. Following the earnings report the stock price went up 0.374%.
Which hedge fund is a major shareholder of Joint Corp?
Currently, no hedge funds are holding shares in JYNT
Joint Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (73.70% Upside)
$14.00 (73.70% Upside)
Blogger Sentiment
Neutral
JYNT Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $367.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.53%
12-Months-Change
Fundamentals
Return on Equity
-16.16%
Trailing 12-Months
Asset Growth
-11.23%
Trailing 12-Months
Company Description
Joint Corp
Joint (JYNT) is a technology-driven health and wellness company focused on enhancing the quality of life through innovative products and services aimed at joint health. The company operates in the health supplements sector, providing a range of dietary supplements formulated to support joint function and mobility. Joint combines cutting-edge research with natural ingredients to create solutions that cater to both preventive health and therapeutic needs.
JYNT Company Deck
JYNT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company making strides in refranchising and financial performance, as evidenced by increased system-wide sales and EBITDA growth. However, challenges remain with declining new patient traffic and the need to adjust sales guidance due to macroeconomic headwinds. The focus on pain management and technology enhancements show potential for future growth.View all JYNT earnings summariesJYNT Stock 12 Month Forecast
Average Price Target
$14.00
▲(73.70% Upside)
Technical Analysis
National Healthcare
―
ModivCare
―
US Physical Therapy
―
Astrana Health
―
Oncology Institute
―
Ownership Overview
2.08% Insiders
13.30% Mutual Funds
45.79% Other Institutional Investors
29.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---